MIRA · Mira Pharmaceuticals, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“We do not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.”